Asparlas vs. Daurismo

Asparlas (calaspargase pegol-mknl) and Daurismo (glasdegib) are anti-cancer (antineoplastic) drugs used to treat different types of leukemia.

Asparlas may also be used to reduce lightheadedness, dizziness, and loss of balance (vertigo) caused by diseases that affect the inner ear.

Asparlas is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.

Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude use of intensive induction chemotherapy.

Asparlas and Daurismo are different types of are anti-cancer (antineoplastic) drugs. Asparlas is an asparagine specific enzyme and Daurismo is a hedgehog pathway inhibitor.

Side effects of Asparlas and Daurismo that are similar include diarrhea, shortness of breath, bleeding, pneumonia, and abnormal/irregular heart rate.

Side effects of Asparlas that are different from Daurismo include elevated transaminase, increased bilirubin, pancreatitis, abnormal clotting studies, and hypersensitivity.

Side effects of Daurismo that are different from Asparlas include anemia, fatigue, febrile neutropenia, musculoskeletal pain, nausea, fluid retention/swelling, low blood platelets (thrombocytopenia), decreased appetite, changes in taste, inflammation and ulcers of mucus membranes, constipation, rash, fever, chest pain, muscle spasm, abdominal pain, vomiting, cough, dizziness, headache, low blood sodium (hyponatremia), weight loss, decreased white blood cell count, and kidney problems.

Asparlas may interact with oral contraceptives.

Daurismo may interact with strong CYP3A inhibitors or inducers and QTc prolonging drugs.

Side effects of Asparlas include:

• elevated transaminase,
• bilirubin increased,
• pancreatitis,
• abnormal clotting studies,
• diarrhea,
• hypersensitivity,
• shortness of breath,
• bleeding,
• pneumonia, and
• abnormal heart rate

This is not a complete list of side effects, and others may occur.

Common side effects of Daurismo include:

• anemia,
• fatigue,
• bleeding,
• febrile neutropenia,
• musculoskeletal pain,
• nausea,
• fluid retention/swelling,
• low blood platelets (thrombocytopenia),
• shortness of breath,
• decreased appetite,
• changes in taste,
• inflammation and ulcers of mucus membranes,
• constipation,
• rash,
• fever,
• chest pain,
• muscle spasm,
• abdominal pain,
• diarrhea,
• vomiting,
• cough,
• dizziness,
• headache,
• pneumonia,
• low blood sodium (hyponatremia),
• weight loss,
• decreased white blood cell count,
• irregular heart rate, and
• kidney problems.

This is not a complete list of side effects, and others may occur.

Asparlas (calaspargase pegol - mknl) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.

Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude use of intensive induction chemotherapy.

Asparlas may interact with oral contraceptives. Tell your doctor all medications and supplements you use.

Daurismo may interact with strong CYP3A inhibitors or inducers, and QTc prolonging drugs.

The recommended dose of Daurismo is 100 mg orally, once daily.